ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Are There Socio-Demographic Inequalities in the Utilisation of Tumour and ctDNA Somatic Mutation Testing in Solid Tumours? A Systematic Review.Cancer medicine · 2026Pooled it
- Germline determinants of risk and molecular subtype in young-onset lung cancer.medRxiv : the preprint server for health sciences · 2026Article
- EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.Cancer immunology, immunotherapy : CII · 2026Article
- PYCR1 promotes glutamine metabolism and the progression of lung adenocarcinoma by regulating the expression of OPLAH.Clinical and experimental medicine · 2026Article
- Somatic copy number variation as a prognostic marker for recurrence in never-smokers with early-stage lung adenocarcinoma.International journal of cancer · 2026Article
- A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.Cancer discovery · 2026Review
- Integrating bulk and single-cell sequencing reveals cellular heterogeneity between lung adenocarcinoma in smokers and never-smokers.Journal of biomedical research · 2026Article
- Article
- Screening air pollutants-related genes to construct a prognostic risk model for lung adenocarcinoma and analyzing its immune microenvironment.Journal of thoracic disease · 2026Article
- Development and validation of a 5mC-based prognostic model for lung adenocarcinoma survival.Cell reports. Medicine · 2026Article
- Microbiota characteristics in different lung tissue sites of female patients with invasive adenocarcinoma.BMC microbiology · 2026Article
- The Landscape of Clinical Trials in Never-Smoker Non-Small-Cell Lung Cancer: Registered Evidence and Persistent Gaps.Cancers · 2026Article
- First-line treatment strategies forJournal of thoracic disease · 2026Article
- Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances.Diagnostics (Basel, Switzerland) · 2026Review
- Cancer Drug Development in Never-Smoker Lung Cancer: Targeted and Immune-Based Therapeutic Strategies.Oncology research · 2026Review
- Integration of single-cell and bulk transcriptomics reveals the association of manganese metabolism-related genes with prognosis and immune infiltration in lung adenocarcinoma.Clinical & translational immunology · 2026Article
- Prognosis, imaging characteristics, and clinicopathological features of heavy smokers with clinical stage I lung adenocarcinoma: a multicenter study.General thoracic and cardiovascular surgery · 2026Article
- Case Report: Synchronous ALK-positive laryngeal inflammatory myofibroblastic tumor and EGFR-mutant lung adenocarcinoma in a child.Frontiers in pediatrics · 2026Article
- Looking through the particles: a narrative review of air pollution and lung cancer.Journal of thoracic disease · 2025Review
- Adverse predictive value of ASPM on lung adenocarcinoma overall survival depended on chemotherapy status.Future science OA · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors at 7 institutions in 1 country.
Funding
Abstract
purposeApproximately 10%-40% of patients with lung cancer report no history of tobacco smoking (never-smokers). We analyzed whole-exome and RNA-sequencing data of 160 tumor and normal lung adenocarcinoma (LUAD) samples from never-smokers to identify clinically actionable alterations and gain insight into the environmental and hereditary risk factors for LUAD among never-smokers.
methodsWe performed whole-exome and RNA-sequencing of 88 and 69 never-smoker LUADs. We analyzed these data in conjunction with data from 76 never-smoker and 299 smoker LUAD samples sequenced by The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium.
resultsWe observed a high prevalence of clinically actionable driver alterations in never-smoker LUADs compared with smoker LUADs (78%-92%
conclusionIn this comprehensive genomic and transcriptome analysis of never-smoker LUADs, we observed a potential role for germline variants in DNA repair genes and passive exposure to cigarette smoke in the pathogenesis of a subset of never-smoker LUADs. Our findings also show that clinically actionable driver alterations are highly prevalent in never-smoker LUADs, highlighting the need for obtaining biopsies with adequate cellularity for clinical genomic testing in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.